ATE291020T1 - Pyrazolderivate gegen tgf überexprimierung - Google Patents

Pyrazolderivate gegen tgf überexprimierung

Info

Publication number
ATE291020T1
ATE291020T1 AT02719740T AT02719740T ATE291020T1 AT E291020 T1 ATE291020 T1 AT E291020T1 AT 02719740 T AT02719740 T AT 02719740T AT 02719740 T AT02719740 T AT 02719740T AT E291020 T1 ATE291020 T1 AT E291020T1
Authority
AT
Austria
Prior art keywords
overexpression
pyrazole derivatives
derivatives against
against tgf
tgf
Prior art date
Application number
AT02719740T
Other languages
English (en)
Inventor
Francoise Jeanne Gellibert
Neil Mathews
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0102661A external-priority patent/GB0102661D0/en
Priority claimed from GB0119424A external-priority patent/GB0119424D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE291020T1 publication Critical patent/ATE291020T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AT02719740T 2001-02-02 2002-01-30 Pyrazolderivate gegen tgf überexprimierung ATE291020T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0102661A GB0102661D0 (en) 2001-02-02 2001-02-02 Compounds
GB0119424A GB0119424D0 (en) 2001-08-09 2001-08-09 Compounds
PCT/EP2002/000938 WO2002066462A1 (en) 2001-02-02 2002-01-30 Pyrazole derivatives against tgf overexpression

Publications (1)

Publication Number Publication Date
ATE291020T1 true ATE291020T1 (de) 2005-04-15

Family

ID=26245671

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02719740T ATE291020T1 (de) 2001-02-02 2002-01-30 Pyrazolderivate gegen tgf überexprimierung

Country Status (8)

Country Link
US (1) US20040087623A1 (de)
EP (1) EP1355903B1 (de)
JP (1) JP2004521915A (de)
AR (1) AR035777A1 (de)
AT (1) ATE291020T1 (de)
DE (1) DE60203263T2 (de)
ES (1) ES2237671T3 (de)
WO (1) WO2002066462A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1397364T1 (sl) 2001-05-24 2007-12-31 Lilly Co Eli Novi pirolni derivati kot farmacevtske uäśinkovine
JP4399265B2 (ja) 2001-12-21 2010-01-13 ヴァーナリス（ケンブリッジ）リミテッド ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用
IL158314A0 (en) * 2001-12-26 2004-05-12 Du Pont Electroluminescent iridium compounds with fluorinated phenylpyridines, phenylpyrimidines, and phenylquinolines and devices made with such compounds
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
GB0217780D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
GB0217787D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd C ompounds
GB0217786D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
EP1539748A1 (de) * 2002-07-31 2005-06-15 Smithkline Beecham Corporation 2-phenylpyridin-4-ylderivate als alk5-inhibitoren
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
WO2004026871A1 (en) * 2002-09-17 2004-04-01 Eli Lilly And Company Novel pyrazolopyridine derivatves as pharmaceutical agents
WO2004026306A2 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
CN1681805A (zh) 2002-09-18 2005-10-12 辉瑞产品公司 作为转化生长因子(tgf)抑制剂的新的咪唑类化合物
KR20050057441A (ko) 2002-09-18 2005-06-16 화이자 프로덕츠 인코포레이티드 전환 성장 인자 억제제로서의 신규한 아이소티아졸 및아이속사졸 화합물
JP2006502236A (ja) 2002-09-18 2006-01-19 ファイザー・プロダクツ・インク 形質転換成長因子（ｔｇｆ）阻害剤としてのトリアゾール誘導体
MXPA05002332A (es) 2002-09-18 2005-06-08 Pfizer Prod Inc Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf).
WO2004048381A2 (en) * 2002-11-22 2004-06-10 Eli Lilly And Company Pyrazoloazepine compounds as pharmaceutical agents
US7405299B2 (en) 2002-11-27 2008-07-29 Eli Lilly And Company Compounds as pharmaceutical agents
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
CA2520804A1 (en) 2003-04-03 2004-10-28 Merck & Co., Inc. Biaryl substituted pyrazoles as sodium channel blockers
CN101553254A (zh) 2006-10-03 2009-10-07 建新公司 TGF-β拮抗物治疗具有罹患支气管肺发育不良风险的婴儿的用途
BRPI0815042A2 (pt) * 2007-08-01 2015-02-10 Pfizer Compostos de pirazol
US8063152B2 (en) * 2008-03-17 2011-11-22 The Goodyear Tire & Rubber Company Boron containing functionalizing agent
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
US9468612B2 (en) 2011-10-26 2016-10-18 Seattle Children's Hospital Cysteamine in the treatment of fibrotic disease
GR1007832B (el) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
CN103351333B (zh) * 2013-06-19 2015-08-26 临海市联盛化学有限公司 一种芳基吡啶衍生化合物及其制备方法
CN103351331B (zh) * 2013-07-16 2015-03-04 临海市联盛化学有限公司 一种海洋天然产物Echinoclathrine A的制备方法
US10899741B2 (en) 2016-11-14 2021-01-26 Jiangsu Hengrui Medicine Co., Ltd. 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
BR112022010251A2 (pt) * 2019-11-28 2022-09-06 Origo Biopharma S L Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento beta
EP3978487A1 (de) * 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-chinolin-4-yl-pyrazol-1-yl)-acetamid-derivate als inhibitoren des transformierenden wachstumsfaktor-beta-rezeptors i/alk5
KR20250051687A (ko) * 2022-08-08 2025-04-17 메디노 파마슈티컬 테크놀로지 (주하이) 컴퍼니 리미티드 TGF-β 억제제 화합물 및 그 사용
WO2025111251A1 (en) * 2023-11-20 2025-05-30 Exelixis, Inc. Compounds that inhibit polo-like kinase 4

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932576A (en) * 1997-05-22 1999-08-03 G. D. Searle & Company 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds

Also Published As

Publication number Publication date
DE60203263T2 (de) 2006-02-09
WO2002066462A1 (en) 2002-08-29
EP1355903A1 (de) 2003-10-29
EP1355903B1 (de) 2005-03-16
JP2004521915A (ja) 2004-07-22
AR035777A1 (es) 2004-07-14
DE60203263D1 (de) 2005-04-21
ES2237671T3 (es) 2005-08-01
US20040087623A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
DE60203263D1 (de) Pyrazolderivate gegen tgf überexprimierung
ATE425147T1 (de) Imidazolderivate
ATE319451T1 (de) Tetrahydrochinolin-derivate
ATE312827T1 (de) 3-substituierte-4-pyrimidonderivate
ATE333445T1 (de) Pyrazolderivate
NO20042356L (no) Tioetersubstituerte imidazokinoliner
ATE361281T1 (de) Substituierte phenylderivate
ATE370120T1 (de) Substituierte 2-pyridin-cyclohexan-1,4- diaminderivate
DE60225563D1 (de) 4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
PL367532A1 (pl) Pochodne diaminy
DE60126286D1 (de) Substituierte pyrazole
DE60204770D1 (de) Scharnier
DE60229183D1 (de) Leitschaufel-Verstellantrieb
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
ATE335740T1 (de) Ringannelierte pyrazolderivate
NO20033828L (no) Peptiddeformylaseinhibitorer
DE60223031D1 (de) Arylpiperazin gebundene tetrahydroindolonderivate
DE60211116D1 (de) Ausgleichsmechanismus
ATE382601T1 (de) Substituierte 4-aminocyclohexanolderivate
DE60202381D1 (de) Paroxetin-n-formyl-derivate
DE50202045D1 (de) Leitungsanordnung
DE60206558D1 (de) Beschichtung
FI20010875A0 (fi) Sarana
GB0108999D0 (en) Pyrazole derivatives
AP2002002469A0 (en) Pyrazole derivatives

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties